Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
Cancer Prev Res (Phila). 2011 May;4(5):628-32. doi: 10.1158/1940-6207.CAPR-11-0162.
There is an increasing recognition that the mutations accompanying carcinogenesis may provide a window of therapeutic advantage designated synthetic lethality, an example of which is reported in this issue of the journal by Huang and colleagues (beginning on page 666). First discovered and studied in yeast, synthetic lethality has basic principles that have encouraged its development for treatment and now prevention in animal models of human cancer, especially malignancies refractory to standard approaches. The pros and cons of this approach and challenges in implementing it clinically are discussed.
人们越来越认识到，伴随致癌过程的突变可能提供了一个治疗优势窗口，被称为合成致死性，这在本期杂志 Huang 和同事的报告中有所体现（见第 666 页开始）。该概念最初在酵母中被发现和研究，具有基本原则，这鼓励了其在人类癌症动物模型中的治疗和现在的预防中的发展，特别是在对抗标准方法有抗性的恶性肿瘤中。本文讨论了这种方法的优缺点和临床实施中的挑战。
